# A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients

> **NCT04197479** · PHASE3 · COMPLETED · sponsor: **Madrigal Pharmaceuticals, Inc.** · enrollment: 1343 (actual)

## Conditions studied

- Non-Alcoholic Fatty Liver Disease

## Interventions

- **DRUG:** Placebo
- **DRUG:** Resmetirom

## Key facts

- **NCT ID:** NCT04197479
- **Lead sponsor:** Madrigal Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-16
- **Primary completion:** 2023-01-06
- **Final completion:** 2023-01-06
- **Target enrollment:** 1343 (ACTUAL)
- **Last updated:** 2023-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04197479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04197479, "A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04197479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*